ToxiProofAI Safe Patient Treatments Powered by AI-PGx
Personalised Precision Medicine Safety.
Safe Trials.
ToxiProofAI Safe Patient Treatments Powered by AI-PGx
Personalised Precision Medicine Safety.
Safe Trials.
Our Mission
Safety discovered late is safety discovered too late
Late-stage clinical trial failures due to safety issues create outsized damage across the healthcare system—exactly the problem ToxiProofAI is built to solve. For health economics, these failures burn hundreds of millions in avoidable R&D spend and strain already limited innovation budgets. For patients, they mean delayed access to life-saving therapies and unnecessary exposure to safety risks that surface far too late. For drug developers, late safety surprises erase years of investment, destabilize pipelines, and increase regulatory and investor pressure—making early, accurate safety insight not just valuable, but essential.
Safety discovered early is safety delivered
ToxiProofAI is a personalised clinical intelligence company operating upstream of trials, regulators, and prescribing. We model potential toxicity risk signals before clinical exposure using biologically grounded pharmacogenomic models powered by advanced biosensors and deep toxicology expertise. We support regulatory-ready evidence generation, enabling safer trials, fewer late-stage failures, and faster, more confident go/no-go decisions for next-generation therapies. We are committed to personalised precision medicine safety. We build the clinical-grade genomic safety layer for patient-level decision-making
Patients at the Center of Safety
Adverse drug reactions don’t just happen on paper — they happen to people. For patients, a single adverse event can trigger physical harm, emotional distress, financial strain, and fear of continuing treatment. What starts as a medical setback can ripple into missed work, reduced quality of life, and loss of trust in care. When reactions are serious, related to treatment, or unexpected, the stakes rise even higher. Understanding how adverse events are identified and escalated isn’t just regulatory—it’s patient protection. Strong pharmacovigilance puts patients first by catching risks early, improving safety decisions, and ensuring treatments are safe. We aim to make proactive (not reactive) patient-level risk scoring to be a core part of active clinical trials.
Turning patient-level genomic insights into potential safety signals
Our pharmacogenomics engine leverages genomic sequences to capture the full genetic context driving drug response and safety risk. AI-driven de-centralized federated learning insights are validated by wet-lab biosensors, anchoring predictions in real biological evidence. At the patient level, our proprietary metrics — CIS, ESS, and DDH—support biomarker-informed stratification research while unlocking new opportunities for drug repurposing, indication selection, and indication expansion. Together, this integrated approach surfaces safety and efficacy signals early, reducing late-stage failures and enabling truly personalized therapeutics.Personalized precision medicine safety prediction designed for translational and research integration is our strength.
Proactive personalised genomic safety stratification
ToxiProofAI advances pharmacogenomics from reactive analysis to proactive, biomarker-driven safety assessment. Our platform identifies potential toxicity-associated genomic risk signals to support stratification, subgroup evaluation, and regulatory-aligned risk assessment in clinical development. ToxiProofAI emphasizes mechanism- and biomarker-based analysis rather than race-based categorization. Population-level findings are interpreted cautiously and evaluated across diverse cohorts to support robust, equitable, and clinically meaningful safety insights.
Innovative Solutions
FlyWheelAI
PGx Biosensors
MySafetyAI™
Our proprietary pharmacogenomics engine -where AI meets biology to uncover hidden safety signals before they reach patients. Our proprietary metrics — CIS, ESS, and DDH—enable precise patient stratification.
MySafetyAI™
PGx Biosensors
MySafetyAI™
A secure, cloud-based app that keeps health enthusiasts, patients and doctors continuously informed about their health. Your go-to source for safety, dosing, and toxicity details about the chemicals around you.
PGx Biosensors
PGx Biosensors
Clinical Trial Support
De-risk your pipeline with tailored PGx insights and validation biosensors for preclinical wet-lab experimentation. We validate our predictions with wet-lab experimentation.
Clinical Trial Support
Clinical Trial Support
Clinical Trial Support
Optimise clinical trial design and dosing strategies with predictive efficacy, safety modelling. We can include pre-clinical data to customize our algorithms for your projects.
PGx Database
Clinical Trial Support
PGx Knowledge base
Ready-to-use proprietary biosensor libraries for rapid safety and efficacy screening.
PGx Knowledge base
Clinical Trial Support
PGx Knowledge base
Your trusted resource for PGx science, Adverse Drug reactions (ADRs), Drug Development, safety analytics, and latest global regulatory insights.
Newsletter
Upcoming opportunities to meet us
London Venture Capital Network VC Summit 2026
- UK BioSeed event
- OHDSI event
- GA4GH 14th Plenary symposium
- RDA 27th Plenary event
London Venture Capital Network VC Summit 2026
London Venture Capital Network VC Summit 2026
In May 2026, we attended the LVCN Summit at Guildhall, London — a stunning venue hosting over 1,700 founders, investors, vendors, exhibitors, and operators, bringing together a vibrant ecosystem of innovation and collaboration. Proud to be invited at the biggest UK VC gathering of the year.
Read our LinekdIn post here:
The Francis Crick Institute Career Fair
ToxiProofAI <> IFSA collaboration cohort
Our second Industry–Academic collaboration cohort was launched during the Crick Career Fair in May 2026, where we officially opened the call for applications. We’re excited to welcome the next cohort of talented university students, who will learn how to build commercial products in biotech.
Read our LinkedIn post here:
https://tinyurl.com/56ndn8fa
ToxiProofAI <> IFSA collaboration cohort
OBN's 20th anniversary BioTrinity partnering event2026
ToxiProofAI <> IFSA collaboration cohort
Our first Industry–Academic collaboration cohort with IFSA Biosciences Career Accelerator was a great success. Over 12 weeks (Feb-May 2026) in London, we mentored four outstanding US-based STEM students as they learnt how commercial products such as MySafetyAI platform is built.
Read our LinkedIn post here: https://tinyurl.com/ap68shhf
OBN's 20th anniversary BioTrinity partnering event2026
OBN's 20th anniversary BioTrinity partnering event2026
OBN's 20th anniversary BioTrinity partnering event2026
In April 2026, we presented poster on our latest case studies, gave a talk and engaged with present and future investors, partners, collaborators and vendors at 20th anniversary BioTrinity event organised by OBN over 3 days in London.
Read our LinkedIn post here:
Immuno-Mark Summit (Global Series)
OBN's 20th anniversary BioTrinity partnering event2026
OBN's 20th anniversary BioTrinity partnering event2026
In March 2026, ToxiProofAI presented latest updates through talk and fireside chat on our innovative solutions in the ImmunoMark Summit, engaging with an exclusive community of 400+ experts in immuno-oncology, biomarkers, and companion diagnostics, representing leading biopharma companies.
Read our LinkedIn post here:
ImmunoOncology Biomarker Summit
In March 2026, ToxiProofAI delivered a keynote at the Immuno-Oncology & Biomarker Summit, presenting case studies from retrospective clinical trials and highlighting how our solutions play a crucial role in reducing the risk of trial failure caused by toxicity signals.
Read our LinkedIn post here:
6th Ace Clinical Trials Summit and Ace Drug Discovery Summit
In February 2026, our CEO participated in the 6th Ace Clinical Trials and Drug Discovery Summits at Insurance Hall, London, as panelists and speaker discussing the future of responsible AI and building trust in emerging technologies in drug discovery and clinical trials.
Read our LinkedIn post here: https://tinyurl.com/337tu7ek
Career talk: St. George International School, Bulgaria
Career talk: St. George International School, Bulgaria
In February 2026, our CEO delivered a meaningful online career talk to students at St. George International School, sharing insights on biotechnology, AI-driven safety solutions, and careers in the biosciences industry. The session sparked thoughtful discussions and aimed to inspire the next generation of future leaders in biosciences.
Read our LinkedIn post here: https://tinyurl.com/ymb53z3k
AI & Big Data Expo Global
Disruptive Technologies for clinical trials
Career talk: St. George International School, Bulgaria
In February 2026, we participated in the AI & Big Data Expo Global in London, connecting with AI leaders, innovators, and industry experts from across the globe. It was a great opportunity to exchange ideas, explore emerging trends, and discuss potential collaborations and partnerships focused on building responsible and impactful AI solutions.
Read our LinkedIn post here: https://tinyurl.com/bdz3b4ke
Disruptive Technologies for clinical trials
Disruptive Technologies for clinical trials
Disruptive Technologies for clinical trials
In January 2026, we officially launched our core product FlyWheelAI at DTCT conference in London. The strong engagement, meaningful discussions, and impactful demos reinforced that we’re building something truly valuable for the future of AI safety and trust, alongside industry leaders from across pharma and biotech.
Read our LinkedIn post here: https://tinyurl.com/3ay6j895
2025
NHS Genomics Health Summit
UK Biobank Scientific Conference
NHS Genomics Health Summit
In December 2025, we participated in NHS Genomics Health Summit in London, connecting with scientific leaders, regulatory officers, policy makers, health economists, clinicians, genetic consultants and exploring AI-driven innovations in healthcare supporting the UK’s 10-Year Health Plan.
Read our LinkedIn post here: https://tinyurl.com/4n4nf5y4
The European AI conference
UK Biobank Scientific Conference
NHS Genomics Health Summit
In December 2025, we participated in The European AI Conference 2025 at the Google London office, joined roundtable discussions, built new connections in the AI community, and exchanged perspectives on emerging trends, collaboration, and responsible AI development.
Read our LinkedIn post here: https://tinyurl.com/4cerrccw
UK Biobank Scientific Conference
UK Biobank Scientific Conference
NHS England PGx and Medicines Optimisation: Network of Excellence event
In December 2025, at the UK Biobank Conference at Queen Elizabeth II centre, we were thrilled to join discussions on advancing biomedical research through privacy-preserving, federated learning from human data. It was a day of inspiring talks, meaningful connections, and exciting new collaboration opportunities.
Read our LinkedIn post here: https://tinyurl.com/bdfnsbv8
NHS England PGx and Medicines Optimisation: Network of Excellence event
NHS England PGx and Medicines Optimisation: Network of Excellence event
NHS England PGx and Medicines Optimisation: Network of Excellence event
In November 2025, we participated in the NHS England PGx event at Manchester. Our Founder discussed with participants how we are driving AI-powered innovation enhancing personalized precision medicine safety.
Read our LinkedIn post here: https://tinyurl.com/4et7zp82
London HealthTech Roundtable
NHS England PGx and Medicines Optimisation: Network of Excellence event
Drug Discovery Biology and Bioinformatics Strategy Meeting
In October 2025, we attended the London Healthtech Roundtable 2025, hosted by the London Venture Capital Network—uniting investors, founders, scientists, and family offices driving the future of health and life sciences.
Read our LinkedIn post here: https://tinyurl.com/yped2a37
Drug Discovery Biology and Bioinformatics Strategy Meeting
NHS England PGx and Medicines Optimisation: Network of Excellence event
Drug Discovery Biology and Bioinformatics Strategy Meeting
In October 2025, we participated in the Drug Discovery Strategy Summit in London. Our founder shared insights on fit-for-purpose data for de-centralized federated AI in target, biomarker, and drug discovery.
Read our LinkedIn post here: https://tinyurl.com/ywrs2n7d
About Us
Our Philosophy
Chandan Seth Nanda
Our Philosophy
The Tree of Life is a symbol found across cultures, representing connection, growth, and balance. Its roots, trunk, and branches illustrate how all life is linked through common ancestry, showing the evolution and diversification of species over time while connecting life, nature, and knowledge.
Our Vision
Chandan Seth Nanda
Our Philosophy
Our vision is to empower drug developers and put patients at the center of care, leveraging genomic insights and advanced clinical intelligence to create medicines that cure diseases safely, effectively, and equitably across all populations.
Our Logo
Chandan Seth Nanda
Chandan Seth Nanda
We believe in life’s interconnected balance —
our logo reflects the Tree of Life, symbolizing that a medicine should be a product of knowledge, action, and growth, all aimed at improving human life.
Life. Growth. ToxiProofAI.
Expertise, Seamlessly Woven Into Our Solutions
Francesco Iori (DPhil)
Francesco Iori (DPhil)
Francesco Iori (DPhil)
AI & Data Science engineering advisor
Kuldeep S Neote (PhD)
Francesco Iori (DPhil)
Francesco Iori (DPhil)
Senior Commercialisation advisor
Dr. Matthew Williams
Francesco Iori (DPhil)
Dr. Matthew Williams
Senior Medical & Clinical trial advisor
Mark Rosenzweig (PhD)
Francesco Iori (DPhil)
Dr. Matthew Williams
Pharmacogenomics & clinical utility advisor
Sandeep Grover (PhD)
Chaman Chander (DPhil)
Chaman Chander (DPhil)
Genetic Epidemiology advisor
Chaman Chander (DPhil)
Chaman Chander (DPhil)
Chaman Chander (DPhil)
Regulatory affairs advisor
Arpit Ahuja (MBA)
Chaman Chander (DPhil)
Arpit Ahuja (MBA)
Market access & digital growth advisor
Compliance
